Antibodies directed to cyclic citrullinated peptides (anti-CCP) are highly specific for rheumatoid arthritis (RA) and can easily be detected in sera by using commercially available immunoassays. The second version of the anti-CCP test (anti-CCP2) demonstrated high specificity (89 -98%) and good sensitivity (41-88%) for RA. Commercially available ELISA methods from three different companies are on the market. All three CCP2 assays show similar results as all CCP2 assays use the same antigen-coated plates. This study was an evaluation of a new automated method for the determination of anti-CCP2 in a routine laboratory setting. Five hundred and fourty three serum samples were tested for anti-CCP2 within normal routine diagnostic using a commercially available ELISA and retested with a prelaunch version of a new and fully-automated method (EliAe). The results were comparable. The new automated assay is easy to use and demonstrated a diagnostic sensitivity of 80% and specificity of 97%.
Introduction
Rheumatoid arthritis (RA) is the most common inflammatory joint disease with a prevalence between 0.5 and 1% worldwide (Lawrence et al. 1998 ). The diagnosis is mainly based on clinical signs and symptoms according to latest recommendations in 1987 (Arnett et al. 1988) . Within these seven diagnostic criterias, detection of IgM rheumatoid factor (RF) in serum is the only recommended laboratory marker. Though IgM-RF is measured in most studies and is the most often ordered autoantibody test in laboratory diagnosis, its specificity for diagnosing RA is limited. At very low levels IgM-RF is present in sera of most people. High concentrations of IgM-RF are not only detected in RA but also in other conditions with polyclonal stimuli to B-cells like viral and bacterial infections or chronic inflammations other than RA. The need for a better laboratory marker with a higher disease-related specificity and sensitivity was always evident.
A very specific antibody for RA was first described by Nienhuis and Mandema (1964) which is called antiperinuclear factor (APF) as these antibodies bound to constituents of the keratohyaline granules which are located close to the nucleus of buccal mucosa cells of adult people. The APF showed an acceptable sensitivity and compared to RF a much higher specificity (Hoet et al. 1991) . Nevertheless, the test was never used for routine testing in case of practical inconvenience. The test required carefully selected buccal mucosa cells which were differentiated enough to contain the perinuclear factor. Experienced laboratory technicians were needed to perform the test based on indirect immunofluorescence and to recognize the different immunofluorescent patterns.
In 1979, another group of RA specific antibodies, the so-called antikeratin antibodies (AKA) was described (Young et al. 1979) . The AKA bind to keratin-like structures in the cornified layer of stratum corneum. These autoantibodies could easily be detected by indirect immunofluorescence on rat oesophagus cryostat sections and some laboratories started to offer AKA measurement within normal routine diagnostics. The specificity for RA was comparable to APF (Hoet and van Venrooij 1992) and it could be demonstrated that AKA also precede the onset of RA (Kurki et al. 1992) .
It was shown that APF and AKA target the same antigen (Sebbag et al. 1995) identified as the epithelial protein filaggrin (filament aggregating protein) which is involved in the organization of cytoskeletal structures. Several filaggrin subunits result from proteolytical cleavage of profilaggrin during differentiation of epithelial cells. Profilaggrin is first dephosphorylated and about 20% of the basic arginine residues are converted into neutral citrulline residues by the enzyme peptidylarginine deiminase. It has been documented that the modification to a citrulline containing protein is essential for the autoantigenicity of filaggrin (Schellekens et al. 1998 ) and citrullinated fillaggrin is the antigen targeted by APF and AKA. Immunoblotting assays and enzyme-linked immunosorbent assays (ELISA) using filaggrin purified from human skin as antigen detected antifilaggrin antibodies (AFA) in 42% of patients with RA with a specificity of 99% (Vincent et al. 1998) . Using in vitro deiminated recombinant filaggrin increased the number of positive RA sera to 52% (Aho et al. 1999) . Sensitivity and specificity of AFA seemed to be dependent on the method of filaggrin purification and on the difficulty to obtain antigen preparations with reproducable citrullin content. This technical problem could be solved by using isolated citrullinated filaggrin peptides as antigen but it became apparent that sera from different RA patients show different patterns of reactivity indicating the heterogenity of the autoimmune response. Using a combination of nine citrullinated peptide variants a sensitivity of 76% and a specificity of 96% were detected. The test was improved and simplified using a cyclic variant of a citrullinated peptide called anti-cyclic citrullinated peptide (CCP) test. This first anti-CCP test revealed a high diagnostic specificity of about 98% and a sensitivity around 70% (Boekel et al. 2002) . To improve, the anti-CCP test peptides from dedicated libraries of citrullinated peptides were tested with RA sera to select the most reactive species. The selected peptides were made cyclic to ensure the exposure of the antigenic citrulline structure. This investigation resulted in the second generation anti-CCP assay which is sold worldwide as CCP2 assay .
Till the end of 2003, there were three distributors (Euro-Diagnostica, Arnhem, The Netherlands; AxisShield Diagnostics Ltd., Dundee, UK; Inova Diagnostics Inc., San Diego, CA) selling the CCP2 test. CCP2 is a brand name and all commercial available immunoassays use the same antigen and the same antigen-coated plates but differ in working procedures. The results of all three assays are similar (Dubucquoi et al. 2004 , Garcia-Berrocal et al. 2005 . The anti-CCP test has a comparable sensitivity but a much higher specificity than the IgM-RF test in diagnosing RA (Table I) and it is not surprising that anti-CCP testing has increasing acceptance in laboratory medicine. In November 2004, Sweden Diagnostics affiliate of Pharmacia Diagnostics AB Freiburg, Germany, launched the first fully-automated testing system for CCP antibodies called ELIAe CCP. This assay was tested in a prelaunch version on samples collected consecutively from patients coming to the Rheumatology Unit of our hospital.
Materials and methods
Five hundred and forty three serum samples (395 female, 148 male) from outpatients of our hospital were tested for anti-CCP routinely by a commercially available ELISA (Inova Diagnostics Inc.) and retested bulkwise by EliAe-CCP (Sweden Diagnostics affiliate of Pharmacia Diagnostics AB Freiburg), an automated test system for the determination of anti-CCP. The tests of both companies correspond to the so-called anti-CCP2 test. Results were classified according to the recommendations of the manufacturers. The ELISA from Inova categorizes negative (,20 U/ml), weak positive (20 -39 U/ml), moderate positive (40 -59 U/ml) and strong positive (.60 U/ml). EliAe from Pharmacia gave a preliminary recommendation with negative (,7 U/ml), borderline positive (7-10 U/ml) and positive (.10 U/ml). Serum samples were drawn from patients consecutively coming to our hospital with joint problems. CCP was routinely tested in all patients with clinical suspect for RA or other inflammatory joint diseases and from patients with prediagnosed RA but not yet tested on anti-CCP. After detection of anti-CCP with both methods, patients' files were screened to evaluate the diagnosis. RA was diagnosed according to the revised ACR criteria (Arnett et al. 1998 ).
Results
Overall, there was a good agreement in the results of both assays (Table II) . Among the positive samples detected by ELISA, 12 samples were negative by EliAe. These samples were from patients who were diagnosed in 1 case as possible RA, in 4 cases as non-RA and in 7 cases a diagnose was not known.
Thirteen out of 88 positive samples tested by EliAe were negative in the Inova assay. Twelve of these samples were only weak positive with concentrations below 29 U/ml and only one sample from a patient diagnosed as non-RA was strong positive. The 12 weak positive samples were in 8 cases from patients with RA (Table III) . Three samples were moderate to strong positive in ELISA but negative in EliAe. None of these three samples was from a patient with definite or possible RA.
In sera of 66 patients with definite RA (Table IV) , the ELISA and EliAe revealed 45 (68%) and 53 (80%) positive results, respectively. In the group of patients with possible RA, anti-CCP results were identical. In the non-RA group results were almost identical with 11 positive and 317 negative samples in ELISA versus 10 positive and 318 negative samples in EliAe. The diagnostic sensitivity and specificity were 68.2 and 96.9% in the ELISA and 80.3 and 97.0% in the EliAe, respectively. Sera were collected from 16 patients at two different times and analysed blinded. All results were highly reproducible in both assay systems though all samples were analyzed in different assay runs.
Discussion
Antibodies directed to citrullinated proteins and their association to RA are well known since several years. These antibodies occur in patients with RA and can even be detected in sera years before onset of disease symptoms (Kurki et al. 1992 , Rantapaa-Dahlqvist et al. 2003 , Nielen et al. 2004 ). The development of synthetic citrullinated proteins provided the use as antigens in immunoassays. Since test improvement by making cyclic variants of citrullinated peptides as antigens in commercially available ELISAs, there is an increasing interest in testing these antibodies as diagnostic and prognostic markers in patients with RA (Kroot et al. 2000 , Schellekens et al. 2000 , Vasishta 2002 , Bas et al. 2003 , Vencovsky et al. 2003 , Berglin et al. 2004 , Forslind et al. 2004 , van Gaalen et al. 2004a ,b, Kastbom et al. 2004 , Lopez-Hoyos 2004 , Maddali Bongi et al. 2004 , Lindqvist et al. 2005 , Nielen et al. 2005 , Raza et al. 2005 .
In 2004, there were three commercial secondgeneration ELISAs for the measurement of anti-CCP antibodies marketed as anti-CCP2 tests. All CCP-2 The ELISA from Inova categorizes negative ,20 U/ml, weak positive 20-39 U, moderate positive 40-59 U and strong positive (. 60 U). The automated EliAe from Sweden Diagnostics categorizes negative ,7 U, borderline 7 -10 U and positive .10 U. RA  66  45  21  53  13  Possible RA  42  12  30  12  30  Non RA  328  11  317  10  318  Unknown  107  19  88  14  93  Total  543  87  456  89  454 tests use the same second-generation synthetic citrullinated peptide antigen bound to the same surface of a microwell plate. The tests differ in handling procedures and other components of the assay system but reveal similar results. Comparing to one of these three ELISA's, we tested a new and fully automated CCP-2 assay in a prelaunch version. The results were comparable and both assays showed the same specificity. We found some difference between the two assays in sensitivity. This difference is mainly based on 8 samples of RA patients, which were negative in the ELISA and weak positive in the EliAe.
Comparing to data from literature, the sensitivity of 80% for the automated assay fits to results from anti-CCP2 ELISAs with optimum cut-off values (GarciaBerrocal et al. 2005) . IgM rheumatoid factor has been commonly used as serological marker of RA. In all publications, anti-CCP demonstrated a higher specificity and a comparable or slightly higher sensitivity than IgM-RF. There is no doubt that anti-CCP is a valuable serum marker for the diagnosis of RA. Different analytical procedures may be one of the reasons that measurement of IgM-RF is still offered in most laboratories but not anti-CCP. IgM-RF is usually measured automatically on common analyzers, which are used in routine laboratory diagnostics. EliAe anti-CCP is the first fully automated method for the determination of anti-CCP with all advantages of an automated analytical method like standardized conditions and short hands-on-time.
The new automated immunoassay EliAe for measuring anti-CCP is easy to use and shows reliable results with sensitivity and specificity for diagnosing RA comparable to given anti-CCP2 ELISAs on the market.
